-
EP4215549
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4215549
| EP4215549 - ANTI-4-1BB-ANTI-PD-L1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 23.06.2023 Database last updated on 17.07.2024 | |
| Former | The international publication has been made Status updated on 26.03.2022 | Most recent event Tooltip | 24.11.2023 | Change: Validation states | published on 27.12.2023 [2023/52] | 24.11.2023 | Change - extension states | published on 27.12.2023 [2023/52] | Applicant(s) | For all designated states Biotheus Inc. 10B, Building 4 N°1 Keji 7th Road Tangjiawan Town, Xiangzhou District Zhuhai, Guangdong 519080 / CN | [2023/30] | Inventor(s) | 01 /
ZHAI, Tianhang ZHUHAI, Guangdong 519080 / CN | 02 /
MIAO, Xiaoniu ZHUHAI, Guangdong 519080 / CN | 03 /
XU, Yingda ZHUHAI, Guangdong 519080 / CN | 04 /
WANG, Tao ZHUHAI, Guangdong 519080 / CN | 05 /
TSUN, Andy ZHUHAI, Guangdong 519080 / CN | 06 /
HUANG, Weifeng ZHUHAI, Guangdong 519080 / CN | [2023/30] | Representative(s) | Cabinet Nony 11 rue Saint-Georges 75009 Paris / FR | [2023/30] | Application number, filing date | 21868693.9 | 17.09.2021 | [2023/30] | WO2021CN118908 | Priority number, date | CN202010983606 | 17.09.2020 Original published format: CN202010983606 | [2023/30] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022057871 | Date: | 24.03.2022 | Language: | ZH | [2022/12] | Type: | A1 Application with search report | No.: | EP4215549 | Date: | 26.07.2023 | Language: | EN | [2023/30] | Search report(s) | International search report - published on: | CN | 24.03.2022 | Classification | IPC: | C07K16/46, C12N15/13, A61K39/395, A61K47/68 | [2023/30] | CPC: |
A61P35/00 (EP,CN,KR,US);
C07K16/2878 (EP,CN,KR);
C07K16/2827 (EP,CN,KR);
C07K16/468 (US);
A61K47/6835 (CN,KR);
C07K16/2818 (KR);
G01N33/56966 (CN,KR);
G01N33/57407 (CN,KR);
G01N33/57484 (CN,KR);
G01N33/6854 (CN,KR);
A61K2039/505 (EP,CN,KR);
C07K2317/22 (EP);
C07K2317/31 (EP,CN,KR,US);
C07K2317/52 (CN,KR,US);
C07K2317/524 (EP);
C07K2317/526 (EP);
C07K2317/565 (US);
C07K2317/569 (EP,CN,KR);
C07K2317/64 (EP);
C07K2317/71 (EP);
C07K2317/73 (CN,KR);
C07K2317/75 (EP);
C07K2317/76 (EP,CN);
C07K2317/90 (EP);
C07K2317/92 (CN,KR);
C07K2317/94 (EP,CN,KR);
C07K2319/21 (CN);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/30] | Title | German: | BISPEZIFISCHER ANTI-4-1BB-ANTI-PD-L1-ANTIKÖRPER SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNG UND VERWENDUNG DAVON | [2023/30] | English: | ANTI-4-1BB-ANTI-PD-L1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | [2023/30] | French: | ANTICORPS BISPÉCIFIQUE ANTI-4-1BB-ANTI-PD-L1, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES | [2023/30] | Entry into regional phase | 30.03.2023 | Translation filed | 30.03.2023 | National basic fee paid | 30.03.2023 | Search fee paid | 30.03.2023 | Designation fee(s) paid | 30.03.2023 | Examination fee paid | Examination procedure | 30.03.2023 | Amendment by applicant (claims and/or description) | 30.03.2023 | Examination requested [2023/30] | Fees paid | Renewal fee | 02.10.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | |||